Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Linehan, D. C.
Right arrow Articles by Eberlein, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Linehan, D. C.
Right arrow Articles by Eberlein, T. J.

Annals of Surgical Oncology, Vol 3, Issue 2 219-228, Copyright © 1996 by Society of Surgical Oncology

ARTICLES

Vaccine therapy for cancer

D. C. Linehan, P. S. Goedegebuure and T. J. Eberlein
Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.

BACKGROUND: Tumor-specific cytotoxic T-lymphocytes (CTLs) can be isolated from the solid tumors, draining lymph nodes, metastatic effusions, and peripheral blood of cancer patients. Despite this evidence for a cell-mediated immune response to cancer, attempts at active specific immunotherapy using cancer vaccines have met with little success in clinical trials. METHODS: We have reviewed the immunobiology of the cell-mediated immune response to cancer by focusing on what is known about the major histocompatibility complex (MHC)-restricted interaction between tumor cells and CD8+ or CD4+ T-cells. In addition, we review the recent advances in the identification of tumor-associated antigens (TAAs) that are recognized by tumor-specific CTLs in melanoma and other cancers. In discussing these antigens, we highlight the recent identification of several MHC-restricted antigenic peptides that are recognized by CTLs from patients with melanoma and those with ovarian and breast cancer. We examine the implications that the discovery of these TAAs and peptides will have on the development of new anticancer vaccines. We review the most recent vaccine trials in melanoma and other cancers and focus on current concepts aimed at improving the therapeutic efficacy of future vaccines, including genetically engineered tumor cell vaccines. CONCLUSIONS: With the recent identification of several TAAs and antigenic peptide epitopes in melanoma and other cancers, immunotherapy researchers are now focusing on new strategies for the development of anticancer vaccines. As the repertoire of known TAAs increases and our understanding of the immunobiology of cell-mediated immunity to cancer improves, immunotherapists remain cautiously optimistic in their quest for effective cancer vaccines.


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
K. Narayanan, A. Jaramillo, N. D. Benshoff, L. G. Campbell, T. P. Fleming, J. R. Dietz, and T. Mohanakumar
Response of Established Human Breast Tumors to Vaccination with Mammaglobin-A cDNA
J Natl Cancer Inst, September 15, 2004; 96(18): 1388 - 1396.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. E. Peoples, B. W. Anderson, T. V. Lee, J. L. Murray, A. P. Kudelka, J. T. Wharton, and C. G. Ioannides
Vaccine Implications of Folate Binding Protein, a Novel Cytotoxic T Lymphocyte-recognized Antigen System in Epithelial Cancers
Clin. Cancer Res., December 1, 1999; 5(12): 4214 - 4223.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. S. Goedegebuure and T. J. Eberlein
Vaccine Trials for the Clinician: Prospects for Viral and Non-Viral Vectors
Oncologist, October 1, 1997; 2(5): 300 - 310.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the Society of Surgical Oncology.